[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
3-Jan-2014

[ | E-mail ] Share Share

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
@PennMedNews

Parkinson's patients utilization of deep brain stimulation treatment reduced in demographic groups

PHILADELPHIA -- Among Parkinson's disease (PD) patients, female, black, and Asian patients are substantially less likely to receive proven deep brain stimulation (DBS) surgery to improve tremors and motor symptoms, according to a new report by a Perelman School of Medicine at the University of Pennsylvania researcher who identified considerable disparities among Medicare recipients receiving DBS for Parkinson's disease. The study, published in Neurology, found that patients from neighborhoods of lower socioeconomic status were less likely to receive DBS, regardless of race or sex. And patients of minority-serving physician practices were also less likely to receive DBS, irrespective of race. The study demonstrates a need to adjust policy and incentives to provide state of the art care for all Parkinson's patients.

Parkinson's disease, a progressive neurodegenerative disease, affects more than 2 million Americans and cannot be prevented or halted. DBS is often prescribed for PD patients when pharmacologic treatments are unable to control involuntary movements or decrease effectiveness over time. While DBS is effective, it requires extensive pre-operative testing, is contraindicated for PD patients who have evidence of cognitive impairment or dementia, and includes out-of-pocket costs that may not be covered by Medicare. DBS out-of-pocket costs average around $2,200 (2007 dollars) per year -- 41 percent more than annual non-DBS costs --and would consume approximately 7 percent of the average income in the lowest socioeconomic quartile, potentially limiting the willingness of low-income seniors to consider DBS.

"There are widespread disparities among Parkinson's patients that are restricting equal utilization of evidence-based care, limiting patients' quality of life, and increasing societal and health care costs," said lead study author Allison Willis, MD, Assistant Professor of Neurology and of Epidemiology at Penn Medicine. Dr. Willis collaborated on the study with colleagues from Washington University School of Medicine in St. Louis. "Efforts to overcome these disparities, through policy or reimbursement changes, can benefit elders and socioeconomically disadvantaged patients with Parkinson's disease, as well as other vulnerable groups," said Willis.

Analyzing more than 665,000 Medicare beneficiaries with a Parkinson's diagnosis between 2007 and 2009 - a decade after DBS was approved for Parkinson's disease patients - the team identified 8,420 patients treated with DBS (approximately 1 percent). Nearly 95 percent of DBS recipients were white, and 59 percent were male. Hispanic PD patients were nearly equally represented among DBS (2.2 percent of all cases) and non-DBS cases (1.7 percent), whereas black and Asian populations were significantly underrepresented among DBS cases. Black PD patients accounted for 1 percent of DBS cases, and 5.5 percent of non-DBS cases, while less than 1 percent of Asian PD patients received DBS, compared to 1.5 who did not. Women of all races accounted for 41 percent of DBS cases, but 50 percent of non-DBS cases.

Patients with PD of all races who were treated by physicians with the highest concentrations of minority (Asian, Hispanic or black) patients had at least a 15 percent lower likelihood of receiving DBS, compared to providers caring for a small percentage of minority patients. While the data may not account for those who were offered DBS and refused or who were evaluated and did not qualify for DBS, the study suggests that minority-serving providers may be unlikely to perform or refer any of their Medicare beneficiaries with PD for DBS.

In addition, early data suggest that socioeconomic challenges to patients with fixed incomes may also contribute to the treatment disparities. Further research is needed to compare DBS out-of-pocket costs with standard medical and surgical procedures for other conditions.

Penn researchers will continue to study clinical characteristics and progression of disease in minorities and women, to see if they may account for any of the DBS utilization differences. In addition, they hope to look further into physician and practice characteristics along with local medical resources to determine how care differences contribute to disparities in individual DBS use.

###

The study was supported by several grants from the National Institutes of Health, including the National Institutes of Neurological Disorders and Stroke, and the National center for Advancing Translational Sciences (NS081087, TR000448, TR000450, ES017765). Additional funding was provided by the St. Louis Chapter of the American Parkinson Disease Association and private donors.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.